Clarkston Capital Partners LLC trimmed its holdings in Envista Holdings Co. (NYSE:NVST - Free Report) by 1.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,288,075 shares of the company's stock after selling 59,225 shares during the quarter. Envista comprises 1.6% of Clarkston Capital Partners LLC's portfolio, making the stock its 22nd largest holding. Clarkston Capital Partners LLC owned about 2.49% of Envista worth $82,717,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Envista during the fourth quarter valued at about $53,000. Lecap Asset Management Ltd. bought a new position in Envista during the 4th quarter valued at $281,000. Geode Capital Management LLC boosted its stake in Envista by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company's stock valued at $57,233,000 after purchasing an additional 71,435 shares in the last quarter. Hantz Financial Services Inc. increased its position in shares of Envista by 146.6% during the 4th quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company's stock valued at $2,131,000 after purchasing an additional 65,679 shares during the period. Finally, Norges Bank bought a new stake in shares of Envista in the 4th quarter worth $38,052,000.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on NVST. Morgan Stanley lowered their target price on Envista from $20.00 to $19.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company set a $19.00 target price on shares of Envista in a research note on Saturday, March 8th. UBS Group decreased their price target on shares of Envista from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Monday, March 10th. Piper Sandler increased their price objective on Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, February 3rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a report on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Envista presently has a consensus rating of "Hold" and a consensus price target of $20.18.
Get Our Latest Analysis on Envista
Envista Stock Down 0.7 %
Envista stock traded down $0.11 during trading hours on Friday, hitting $15.43. The company had a trading volume of 711,362 shares, compared to its average volume of 2,474,266. Envista Holdings Co. has a fifty-two week low of $14.22 and a fifty-two week high of $23.00. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The firm has a market capitalization of $2.66 billion, a P/E ratio of -2.37, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. The firm's fifty day moving average is $18.50 and its 200-day moving average is $19.38.
Envista (NYSE:NVST - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, research analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current year.
About Envista
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Articles
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
